67047-06-7

Basic information

• Product Name: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate
• Synonyms: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate
• CAS NO: 67047-06-7
• Molecular Weight: 444.441
• Mol File: 67047-06-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(67047-06-7)
• EPA Substance Registry System: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(67047-06-7)

Safety Data

• Hazardous Substances Data: 67047-06-7(Hazardous Substances Data)

Upstream product

• 67047-05-6 4-oxo-2-phenyl-4H-1-benzopyran-5,6,7-triyl triacetate 
• 100-39-0 benzyl bromide 
• 491-67-8 5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 100-44-7 benzyl chloride 

Downstream Products

• 480-11-5 oroxylin A 
• 1357354-99-4 7-(benzyloxy)-5-hydroxy-4-oxo-2-phenyl-4H-1-benzopyran-6-yl 2-hydroxyacetate 
• 1357354-97-2 7-(benzyloxy)-6-(2-hydroxyethoxy)-5-methoxy-2-phenyl-4H-1-benzopyran-4-one 
• 1357354-95-0 7-(benzyloxy)-5-hydroxy-6-(2-hydroxyethoxy)-2-phenyl-4H-1-benzopyran-4-one 
• 1345982-19-5 5,7-dihydroxy-6-(2-morpholin-4-yl-ethoxy)-flavone 
• 1272971-84-2 5-hydroxy-6-(2-morpholin-4-yl-ethoxy)-7-benzyloxy-flavone 
• 5928-35-8 7-(benzyloxy)-5,6-dihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 21967-41-9 baicalin 
• 57396-78-8 Oroxin A 
• 74293-55-3 5,6-Diacetoxy-7-hydroxyflavon-7-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosid) 
• 74304-67-9 5,6-Diacetoxy-7-hydroxyflavon-7-O-(2,3,4-tri-O-acetyl-β-D-glucopyranosiduronsaeure-methylester) 
• 67047-07-8 5,6-diacetoxy-7-hydroxyflavone 

Relevant articles and documents

Concise synthesis and antidiabetic activity of natural flavonoid glycosides, oroxins C and D, isolated from the seeds of Oroxylum indium

The first concise synthesis of natural flavonoid glycosides, oroxins C (1) and D (2), which were isolated from the seeds of Oroxylum indicum, was efficiently achieved by a convergent strategy. The synthesized natural products 1 and 2 were evaluated for th

Novel synthetic baicalein derivatives caused apoptosis and activated AMP-activated protein kinase in human tumor cells

Studies on the anti-proliferative activities of novel baicalein derivatives demonstrated that compounds 8 and 9 were able to activate AMPK by enhancing the levels of phosphorylated AMPKα, and showed more potent anti-proliferative effects than baicalein an

COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING

The present invention is directed to analogs of baicalein according to formula (I): where R5 is H, (CI-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl group, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group; R6 and R7 are each independently H, (C1-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl or together form a -OCR1R20- group wherein each of R1 and R2 is independently H, a C1-C3 alkyl group or an optionally substituted phenyl or benzyl group; and R8 is H, OH, an O-acyl group, a C1,-C4 alkyl or alkoxy group, F, Cl, Br or I, or a pharmaceutically acceptable salt thereof, which exhibit anti-P-glycoprotein activity and methods of enhancing the bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme, especially CYP450 3A4 enzyme. Pharmaceutical compositions based upon these novel derivatives according to the present invention are also described herein.